» Articles » PMID: 36766461

ECG Changes During Adult Life in Fabry Disease: Results from a Large Longitudinal Cohort Study

Abstract

Fabry disease (FD) is an X-linked, lysosomal storage disorder leading to severe cardiomyopathy in a significant proportion of patients. To identify ECG markers that reflect early cardiac involvement and disease progression, we conducted a long term retrospective study in a large cohort of FD patients. A total of 1995 ECGs from 133 patients with classical FD (64% females, 80% treated with enzyme replacement therapy), spanning 20 years of follow-up, were compared to ECGs from 3893 apparently healthy individuals. Generalized linear mixed models were used to evaluate the effect of age, FD and sex on: P-wave duration, PR-interval, QRS-duration, QTc, Cornell index, spatial QRS-T angle and frontal QRS-axis. Regression slopes and absolute values for each parameter were compared between FD patients and control subjects. At a younger age (<40 years), the Cornell index was higher and frontal QRS-axis more negative in FD patients compared to controls ( < 0.05). For the other ECG parameters, the rate of change, more than the absolute value, was greater in FD patients compared to controls ( < 0.05). From the fifth decade (men) or sixth (women) onwards, absolute values for P-wave duration, QRS-duration, QTc and spatial QRS-T angle were longer and higher in FD patients compared to control subjects. ECG abnormalities indicative of FD are age and sex dependent. Tracking the rate of change in ECG parameters could be a good way to detect disease progression, guiding treatment initiation. Moreover, monitoring ECG changes in FD can be used to evaluate the effectiveness of treatment.

Citing Articles

2024 Update of the TSOC Expert Consensus of Fabry Disease.

Hung C, Wu Y, Kuo L, Sung K, Lin H, Chang W Acta Cardiol Sin. 2024; 40(5):544-568.

PMID: 39308653 PMC: 11413953. DOI: 10.6515/ACS.202409_40(5).20240731A.


Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking.

Parisi V, Baldassarre R, Ferrara V, Ditaranto R, Barlocco F, Lillo R Front Cardiovasc Med. 2023; 10:1184361.

PMID: 37416917 PMC: 10320218. DOI: 10.3389/fcvm.2023.1184361.


Increased cardiac involvement in Fabry disease using blood-corrected native T1 mapping.

Nickander J, Cole B, Nordin S, Vijapurapu R, Steeds R, Moon J Sci Rep. 2023; 13(1):4420.

PMID: 36932097 PMC: 10023696. DOI: 10.1038/s41598-023-31211-9.

References
1.
Rozenfeld P, Feriozzi S . Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017; 122(3):19-27. DOI: 10.1016/j.ymgme.2017.09.004. View

2.
El Sayed M, Hirsch A, Boekholdt M, van Dussen L, Datema M, Hollak C . Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease. Heart. 2021; 107(23):1889-1897. PMC: 8600611. DOI: 10.1136/heartjnl-2020-317922. View

3.
Jogu H, ONeal W, Broughton S, Shah A, Zhang Z, Soliman E . Frontal QRS-T Angle and the Risk of Atrial Fibrillation in the Elderly. Ann Noninvasive Electrocardiol. 2016; 22(2). PMC: 5303692. DOI: 10.1111/anec.12388. View

4.
El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F . Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One. 2017; 12(3):e0173358. PMC: 5351840. DOI: 10.1371/journal.pone.0173358. View

5.
van der Veen S, Korver S, Hirsch A, Hollak C, Wijburg F, Brands M . Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. Mol Genet Metab. 2022; 135(2):163-169. DOI: 10.1016/j.ymgme.2021.12.004. View